This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Altria (MO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Adobe, Costco, Union Pacific, NextEra Energy and Altria Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, Costco, Union Pacific, NextEra Energy and Altria Group
Top Stock Reports for Adobe, Costco & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Costco Wholesale (COST) and Union Pacific (UNP).
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $39.50, moving +1.36% from the previous trading session.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $38.36, moving -1.51% from the previous trading session.
Oral Tobacco Unit Supports Altria Amid Poor Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of low risk tobacco alternatives. However the company's smokeable unit is bearing the brunt of soft cigarette sales.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $38.55, moving -0.7% from the previous trading session.
RRPs a Respite for Philip Morris Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS. However, low cigarette sales is a dampener.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $43 in the latest trading session, marking a -1.35% move from the prior day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $43.49, marking a +0.46% move from the previous day.
Altria (MO) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Altria Gains From Oral Products Amid Lower Cigarette Sales
by Zacks Equity Research
Despite dismal cigarette sales, pricing power and growth in oral tobacco are offering Altria (MO) some respite.
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
Stock Market News for Jul 29, 2020
by Zacks Equity Research
Benchmarks slipped into the negative territory on Tuesday as investors kept a close watch on a second coronavirus relief package in consideration by lawmakers, along with mixed second-quarter corporate earnings report.
Top Stock Reports for AstraZeneca, Union Pacific & Altria
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca (AZN), Union Pacific (UNP) and Altria Group (MO).
Altria's (MO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) second-quarter 2020 results reflect adjusted OCI growth in oral tobacco and smokeable product segments. However, smokeable product revenues decline.
Altria (MO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 2.83% and -0.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's How Altria (MO) is Placed Just Ahead of Q2 Earnings
by Zacks Equity Research
Altria Group's (MO) second-quarter 2020 results are likely to reflect pricing gains. However, cigarette volumes have been affected by regulatory hurdles and rising health consciousness.
Earnings Preview: Altria (MO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $40.87, marking a -1.61% move from the previous day.
Can Altria (MO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria (MO) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $40.21 in the latest trading session, marking a -0.15% move from the prior day.
Philip Morris' (PM) IQOS Gets FDA Nod to be Marketed as MRTP
by Zacks Equity Research
Philip Morris (PM) is likely to benefit from the FDA's latest move. Notably, the FDA authorizes IQOS's marketing as a modified risk tobacco product.